Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
52
IMMP Quote, Financials, Valuation and Earnings
Last price:
$2.78
Seasonality move
:
2.16%
Day range:
$2.73 - $2.86
52-week range:
$1.32 - $3.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
150.04x
P/B ratio:
2.31x
Volume:
295K
Avg. volume:
176.8K
1-year change:
47.37%
Market cap:
$398.8M
Revenue:
--
EPS (TTM):
-$0.37
Analysts' Opinion
-
Consensus RatingImmutep Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.50, Immutep Ltd. has an estimated upside of 246.72% from its current price of $2.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $2.80.
Fair Value
-
According to the consensus of 1 analyst, Immutep Ltd. has 246.72% upside to fair value with a price target of $9.50 per share.
IMMP vs. S&P 500
-
Over the past 5 trading days, Immutep Ltd. has underperformed the S&P 500 by -4.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Immutep Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Immutep Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Immutep Ltd. reported revenues of --.
Earnings Growth
-
Immutep Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Immutep Ltd. reported earnings per share of --.
Enterprise value:
149.1M
EV / Invested capital:
--
Price / LTM sales:
150.04x
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.17x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.2M
Return On Assets:
--
Net Income Margin (TTM):
-2026.1%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2015-06-30 | 2016-06-30 | 2017-06-30 | 2016-06-30 | 2017-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -$280 | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$8.7M | -$2.7M | -$2.7M | |
| EBITDA | -- | -- | -$7.2M | -$2.5M | -$1.5M | |
| Diluted EPS | -- | -- | -$0.12 | $0.12 | -$0.07 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $78M | $51.2M | $77M | $108.1M | -- | |
| Total Assets | $87.1M | $58.5M | $84.3M | $113.4M | -- | |
| Current Liabilities | $5.7M | $5.7M | $4.5M | $5.7M | -- | |
| Total Liabilities | $8.2M | $6.3M | $5.5M | $6.1M | -- | |
| Total Equity | $78.9M | $52.2M | $78.8M | $107.2M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.9M | -$22.9M | -$39.4M | -- | -- | |
| Cash From Investing | -$55.9K | -$13.8M | -$24.4M | -$13.1M | -$5.9M | |
| Cash From Financing | $51.4M | $62.6M | -$333.1K | $62.7M | -$56K | |
| Free Cash Flow | -$23.9M | -$23.5M | -$39.5M | -- | -- | |
IMMP
Sector
Market Cap
$398.8M
$25.8M
Price % of 52-Week High
77.62%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-0%
-1.64%
1-Year Price Total Return
44.21%
-18.88%
Beta (5-Year)
1.756
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.81
200-day SMA
Buy
Level
$2.07
Bollinger Bands (100)
Buy
Level
1.91 - 2.89
Chaikin Money Flow
Sell
Level
-329.5K
20-day SMA
Buy
Level
$2.76
Relative Strength Index (RSI14)
Buy
Level
50.02
ADX Line
Sell
Level
27.74
Williams %R
Neutral
Level
-56.0976
50-day SMA
Sell
Level
$2.86
MACD (12, 26)
Buy
Level
0.48
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-404K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12)
Buy
CA Score
(Annual)
Level (-0.2174)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (6.4839)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Stock Forecast FAQ
In the current month, IMMP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IMMP average analyst price target in the past 3 months is $9.50.
-
Where Will Immutep Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Immutep Ltd. share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About Immutep Ltd.?
Analysts are divided on their view about Immutep Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Immutep Ltd. is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Immutep Ltd.'s Price Target?
The price target for Immutep Ltd. over the next 1-year time period is forecast to be $9.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IMMP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Immutep Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of IMMP?
You can purchase shares of Immutep Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Immutep Ltd. shares.
-
What Is The Immutep Ltd. Share Price Today?
Immutep Ltd. was last trading at $2.78 per share. This represents the most recent stock quote for Immutep Ltd.. Yesterday, Immutep Ltd. closed at $2.80 per share.
-
How To Buy Immutep Ltd. Stock Online?
In order to purchase Immutep Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IMMP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMMP
Sector
P/E ratio
--
23.44x
PEG ratio
-0.17x
-0.01x
P/B ratio
2.31x
1.81x
Price / LTM sales
150.04x
1.56x
Growth Metrics
IMMP
Sector
Revenue growth
--
3.27%
Earnings growth
--
9.66%
Revenue (5-year growth)
-100%
6.43%
Earnings forecast
--
-$0.20
Profitability
IMMP
Sector
Profitability FY 2025
-$1.5M
$2.3M
Return on invested capital
--
-33.49%
Return on assets
--
-29.74%
Return on equity
--
-39.33%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
Sep
2
Estimated Next Earnings Date
May
28
Balance Sheet
IMMP
Sector
Total cash
$99M
$24.2M
Short term investments
$13.4M
$23.8M
Total assets
$102.9M
$71.1M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 28
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
